Pharmacokinetically guided administration of chemotherapeutic agents.
about
The Valley of Death in anticancer drug development: a reassessmentAssociation of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemiaTranslational research on influenza virus infection using a nonhuman primate model.Pharmacokinetics of high-dose chemotherapy.Population pharmacokinetics of raltitrexed in patients with advanced solid tumoursDeterminants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.Therapeutic drug monitoring in cancer chemotherapy.In vitro chemosensitivity of head and neck cancer cell lines.Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.Optimization of cisplatin doses in a testicular cancer patient with acute renal failure.Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs.Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia.Dose calculation of anticancer drugs
P2860
Q26861274-873AF7AD-0987-4104-947D-A04C5158233AQ28538292-B3263D86-7C1E-45CF-97FF-7ABD501E06B4Q30383873-37296F0F-6E22-4DCC-ABD9-EFBCD60BA261Q35597047-A6DC7F06-B47C-4AB4-93EB-B4E69F79E438Q35826027-53C28E42-A611-467A-855A-34BB8F859EBCQ35827596-6E5B0BE5-6FDD-430A-8065-8D059BB1E8D2Q37373689-0E1D3FF6-80D0-4FDF-9862-A205F725D97CQ37810220-DFD5F9BE-86C6-47A3-BA6B-D834EEA507DFQ39643999-B45DC8DD-2B55-4551-B6B7-4A77E5F9B23DQ41882636-DAE4D211-7B79-4A8F-B363-FE1460BF9A34Q42780053-9AC5BE31-D270-4130-A84A-A90FE6BFE7B1Q44198865-63C9CAF2-0A2C-4DAA-8287-B7E726147D1AQ45902992-8CC7D18D-B5F2-44E8-899D-5274EEACFDD5Q50798269-0B11F8BE-83DF-4182-AD4D-EB3D786DDE2AQ51458897-12ADE29A-809F-4F2E-A133-7539D5E7D20CQ54204516-0479C57C-4EA6-45E7-9DD3-99AFDBCDD35CQ56391087-3D3DDE6A-CF65-426C-A6A5-2E0D65A77ACC
P2860
Pharmacokinetically guided administration of chemotherapeutic agents.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacokinetically guided administration of chemotherapeutic agents.
@ast
Pharmacokinetically guided administration of chemotherapeutic agents.
@en
Pharmacokinetically guided administration of chemotherapeutic agents.
@nl
type
label
Pharmacokinetically guided administration of chemotherapeutic agents.
@ast
Pharmacokinetically guided administration of chemotherapeutic agents.
@en
Pharmacokinetically guided administration of chemotherapeutic agents.
@nl
prefLabel
Pharmacokinetically guided administration of chemotherapeutic agents.
@ast
Pharmacokinetically guided administration of chemotherapeutic agents.
@en
Pharmacokinetically guided administration of chemotherapeutic agents.
@nl
P2093
P2860
P1476
Pharmacokinetically guided administration of chemotherapeutic agents.
@en
P2093
Beijnen JH
Schellens JH
van den Bongard HJ
P2860
P304
P356
10.2165/00003088-200039050-00004
P577
2000-11-01T00:00:00Z
P6179
1006146183